Reply to Leibovici et al

Clinical Infectious Diseases

Volumn 51, Issue 11, 2010, Pages 1351-1352

  Kim, Peter W ^a   Nambiar, Sumathi ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CEFEPIME;

CLINICAL TRIAL; DRUG SAFETY; FEBRILE NEUTROPENIA; HUMAN; LETTER; MEDICAL LITERATURE; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; RISK FACTOR; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 78649830775     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/657248     Document Type: Letter

References (6)

1. Leibovici L, Yahav D, Paul M. Meta-analysis of a possible signal of increased mortality associated with cefepime use. Clin Infect Dis 2010; 51:1350-1351 (in this issue).
2. Kim PW, Wu YT, Cooper C, et al. Meta-analysis of a possible signal of increased mortality associated with cefepime use. Clin Infect Dis 2010; 51:381-389.
3. Yahav D, Paul M, Fraser A, Sarid N, Leibovici L. Efficacy and safety of cefepime: a systematic review and meta-analysis. Lancet Infect Dis 2007; 7:338-348.
4. Sanz MA, Lopez J, Lahuerta JJ, et al. Cefepime plus amikacin versus piperacillin-tazobactam plus amikacin for initial antibiotic therapy in haematology patients with febrile neutropenia: results of an open, randomized, multicentre trial. J Antimicrob Chemother 2002; 50:79-88.
5. Food and Drug Administration. Clinical review, NDA 50-679, cefepime. http://www.fda.gov/ downloads/Drugs/DrugSafety/PostmarketDrug SafetyInformationforPatientsandProviders/Drug SafetyInformationforHeathcareProfessionals/ UCM167313.pdf. Accessed 30 July 2010.
6. Food and Drug Administration. Statistical review and evaluation, NDA 50-679, cefepime hydrochloride. http://www.fda.gov/downloads/ Drugs/DrugSafety/PostmarketDrugSafetyInfor mationforPatientsandProviders/ DrugSafetyIn formationforHeathcareProfessionals/UCM 167309.pdf. Accessed 30 July 2010.